Bevacizumab in the treatment of breast cancer

Expert Review of Anticancer Therapy

Volumn 8, Issue 10, 2008, Pages 1559-1568

  Sirohi, Bhawna ^a   Smith, Katy ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Bevacizumab; Breast cancer; Phase III data; Targeted therapy

Indexed keywords

ANASTROZOLE; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ANTICOAGULANT AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EVEROLIMUS; FULVESTRANT; GEMCITABINE; IRINOTECAN; IXABEPILONE; LAPATINIB; LETROZOLE; N (3,3 DIMETHYL 6 INDOLINYL) 2 (4 PYRIDINYLMETHYLAMINO)NICOTINAMIDE; NAVELBINE; PACLITAXEL; PLACEBO; SORAFENIB; SUNITINIB; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; UNINDEXED DRUG; VASCULOTROPIN; VORINOSTAT;

ADJUVANT THERAPY; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CARDIOMYOPATHY; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; CYTOSTASIS; DEEP VEIN THROMBOSIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EARLY CANCER; ELDERLY CARE; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL HEMORRHAGE; HEART ARRHYTHMIA; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; LEUKOENCEPHALOPATHY; LUNG EMBOLISM; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NOSE CONGESTION; PROTEINURIA; RECOMMENDED DRUG DOSE; SIDE EFFECT; SINUS CONGESTION; THROMBOEMBOLISM; THROMBOSIS; VEIN THROMBOSIS; VOMITING; WOUND DEHISCENCE; WOUND HEALING IMPAIRMENT;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; HUMANS; NEOPLASM METASTASIS;

EID: 55249094604     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.10.1559     Document Type: Article

References (33)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285(21), 1182-1186 (1971).
2. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86(3), 353-364 (1996).
3. Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin. Oncol. 29(6 Suppl. 16), 10-14 (2002).
4. Millauer B, Longhi MP, Plate KH et al. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res. 56(7), 1615-1620 (1996).
5. Weidner N, Folkman J, Pozza F et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J. Natl. Cancer Inst. 84(24), 1875-1887 (1992).
6. Hayes DF, Miller K, Sledge G. Angiogenesis as targeted breast cancer therapy. Breast 16(Suppl. 2), S17-S19 (2007).
7. Marty M, Pivot X. The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab. Eur. J. Cancer 44(7), 912-920 (2008).
8. Gordon MS, Margolin K, Talpaz M et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol. 19(3), 843-850 (2001).
9. Cobleigh MA, Langmuir VK, Sledge GW et al. A Phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin. Oncol. 30(5 Suppl. 16), 117-124 (2003).
10. Miller KD, Chap LI, Holmes FA et al. Randomized Phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J. Clin. Oncol. 23(4), 792-799 (2005).
11. Relf M, LeJeune S, Scott PA et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor β-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 57(5), 963-969 (1997).
12. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357(26), 2666-2676 (2007).
13. Miles D, Chan A, Romieu G et al. Randomized, double-blind, placebo-controlled, Phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. J. Clin. Oncol. 26, (2008) (Abstract 1011).
14. Sledge G, Miller K, Moisa C, Gradishar W. Safety and efficacy of capecitabine (C) plus bevacizumab (B) as first-line in metastatic breast cancer. J. Clin. Oncol. 25(18S) (2007) (Abstract 1013).
15. Pierga J, Pritchard KI, Cortes-Funes L et al. MO19391: an open-label safety study of bevacizumab plus taxane-based therapy as first-line treatment of patients with locally recurrent (LR) or metastatic breast cancer (MBC). J. Clin. Oncol. 26, (2008) (Abstract 1140).
16. Lyons JA, Silverman P, Remick S et al. Toxicity results and early outcome data on a randomized Phase II study of docetaxel±bevacizumab for locally advanced, unresectable breast cancer. J. Clin. Oncol. 24 (Suppl. 18), 133S (2006).
17. Greil R, Moik M, Reitsamer R et al. Capecitabine + docetaxel + bevacizumab as neoadjuvant therapy for invasive breast cancer: results of a Phase II pilot study. Presented at: 30th Annual San Antonio Breast Cancer Symposium. TX, USA, 13-16 December, 2007 (Abstract 4064).
18. Cameron D, Bell R. Future use of bevacizumab and other anti-angiogenic agents in breast cancer. Eur. J. Cancer 6, 40-50 (2008).
19. Forero-Torres A, Galleshaw J, Jones C et al. A pilot open-label trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed operable breast cancer. J. Clin. Oncol. 26 (2008) (Abstract 625).
20. Miller KD, O'Neill A, Perez EA, Seidman AD, Sledge GW. Phase II feasibility trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node-positive breast cancer: a trial of the Eastern Cooperative Oncology Group (E2104). J. Clin. Oncol. 26 (2008) (Abstract 520).
21. Hart LL, Badrinath S, Waterhouse DM et al. A multicenter study of 3 docetaxel regimens with bevacizumab as adjuvant therapy for breast cancer (BC): preliminary results. J. Clin. Oncol. 26 (2008) (Abstract 575).
22. Pegram M, Chan D, Dichmann RA et al. Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first line treatment of HER2- amplified breast cancer. Breast Cancer Res. Treat. 100(Suppl. 1), S28 (2006).
23. + metastatic breast cancer (MBC). J. Clin. Oncol. 26(Suppl.) (2008) (Abstract 1042).
24. Vredenburgh JJ, Desjardins A, Herndon JE et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol. 25(30), 4722-4729 (2007).
25. Labidi S, Bachelor T, Ray Coquard IL, Favier B, Galy G, Guastalla J. Bevacizumab and paclitaxel for breast cancer patients with CNS metastases. J. Clin. Oncol. 26 (2008) (Abstract 12009).
26. Beatty GL, Giantonio BJ. Bevacizumab and oxaliplatin-based chemotherapy in metastatic colorectal cancer. Expert Rev. Anticancer Ther. 8(5), 683-688 (2008).
27. Gutierrez M, Giaccone G. Antiangiogenic therapy in nonsmall cell lung cancer. Curr. Opin. Oncol. 20(2), 176-182 (2008).
28. Cameron D. Bevacizumab in the first-line treatment of metastatic breast cancer. Eur. J. Cancer 6, 21-28 (2008).
29. Hoff PM. Bevacizumab in older patients and patients with poorer performance status. Semin. Oncol. 33(5 Suppl. 10), S19-S25 (2006).
30. Richardson S, Dickler M, Dang CT, Hudis CA, Traina TA. Tolerance of bevacizumab in an older patient population: The Memorial Sloan-Kettering Cancer Center (MSKCC) experience. J. Clin. Oncol. 26(Suppl.) (2008) (Abstract 9569).
31. Berry S, Michael M, Kretzschmar A et al. Lack of effect of starting bevacizumab shortly after venous access device implantation on wound healing/bleeding complications: preliminary results from first BEAT. Proceedings of: Gastrointestinal Cancers Symposium. CA, USA (2006) (Abstract 245).
32. Wedam SB, Low JA, Yang SX et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J. Clin. Oncol. 24(5), 769-777 (2006).
33. Glusker P, Recht L, Lane B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N. Engl. J. Med. 354(9), 980-982 (2006).